Table 2.
Adverse events considered possibly related to BLZ-100.
| Cohort 1 1 mg BLZ-100 (N = 3) n (%) |
Cohort 2 3 mg BLZ-100 (N = 3) n (%) |
Cohort 3 6 mg BLZ-100 (N = 6) n (%) |
Cohort 4 12 mg BLZ-100 (N = 6) n (%) |
Cohort 5 18 mg BLZ-100 (N = 3) n (%) |
All Subjects (N = 21) n (%) | |
|---|---|---|---|---|---|---|
| Subjects with at least one AE considered possibly related to BLZ-100 | 3 (100) | 0 (0.0) | 1 (16.7) | 0 (0) | 1 (33.3) | 5 (23.8) |
| Headache | 0 (0.0) | 0 (0.0) | 1 (16.7) | 0 (0.0) | 1 (33.3) | 2 (9.5) |
| Nausea | 0 (0.0) | 0 (0.0) | 1 (16.7) | 0 (0.0) | 1 (33.3) | 2 (9.5) |
| Abdominal pain | 1 (33.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (4.8) |
| Abdominal pain upper | 1 (33.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (4.8) |
| Dysgeusia | 1 (33.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (4.8) |
| Frequent bowel movements | 1 (33.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (4.8) |
| Pruritus | 1 (33.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (4.8) |
This table presents the number of subjects with an adverse event considered possibly related to BLZ-100 and the percentage of total subjects. Percentages are based on the total number of subjects. Events are presented by decreasing incidence in the “All Subjects” column.
Adverse events are coded according to Medical Dictionary for Medical Activities (MedDRA) Version 17.1 system organ class and preferred terms.